Ono Pharmaceutical Co. (OTCMKTS:OPHLF) Short Interest Up 98.7% in June

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) saw a significant increase in short interest in June. As of June 15th, there was short interest totaling 1,994,790 shares, an increase of 98.7% from the May 31st total of 1,003,767 shares. Based on an average daily volume of 3 shares, the days-to-cover ratio is presently 664,930.0 days. Approximately 0.4% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Ono Pharmaceutical to a “hold” rating in a research report on Friday, April 17th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Ono Pharmaceutical Stock Performance

Shares of OTCMKTS OPHLF opened at $13.50 on Wednesday. Ono Pharmaceutical has a 1-year low of $9.20 and a 1-year high of $18.67. The business has a fifty day moving average price of $14.40 and a 200 day moving average price of $14.58. The stock has a market capitalization of $6.34 billion, a P/E ratio of 13.64 and a beta of 0.32. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.